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Migraines are a common disorder in children and observed in 10.6% of children 
aged 5–15 years (1). The mean age of onset of migraine symptoms is 7 year of age 
in boys and 10.9 years of age in girls (2). Frequent migraine attacks may cause 
concern for parents in addition to their impact on the quality of life of children (3). 
Migraine prevalence has increased up to 3 times over the past three decades (4). The 
exact cause of this issue is unknown. However, increased environmental stress and 
changes in diet (increased consumption of caffeine and aspartame in beverages) 
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Objective
The effect of using omega-3 to prevent migraine attacks has been raised in 
recent studies. The majority of these studies have been conducted in adults. 
Conversely, other studies have yet to confirm the effect of omega-3. The main 
purpose of this study was to assess the effects of omega-3 in the prevention of 
migraine attacks in children.
Materials & Methods
In this study, children aged 5–15 years with a diagnosis of migraine were 
randomly assigned to case and control groups. The case group was treated 
with sodium valproate and 1 g of omega-3; the control group was treated 
with sodium valproate and a placebo for 2 months. The severity of attacks 
was evaluated before and after the treatment using PedMIDAS and parental 
satisfaction (CGI) using a 7-point Likert scale.
Results
In this study, 12 cases and 13 controls were enrolled. The average number 
of headache attacks per month decreased significantly in both groups after 
starting the treatment but there was no significant difference between the two 
groups. The severity of attacks decreased significantly in both groups after 
starting the treatment but it was not significant between them. Examination of 
the CGI average showed the average was 6.08 (SD = 0.52) in the case group 
and 6.07 (SD = 0.65) in the control group.
Conclusion
The present study indicated that omega-3 with a dose of 1 mg per day has no 
effect in reducing the severity and frequency of migraine attacks in children. 
Sodium valproate was effective in reducing the frequency and severity of 
attacks.
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well as with frequent attacks (more than one attack per 
week or more than three attacks per month or more 
than one day leaving school per month) were included. 
The Ethics Committee of the Hamadan University of 
Medical Sciences approved our study. Patients were 
divided into two groups of at least 12 individuals and 
matched for age (children aged 5–14 years of age) by 
a simple random sampling method using a random 
number table. The first group (control group) was 
treated with sodium valproate syrup or tablet with 
a dose of 20 mg per kg of body weight (maximum 
200 mg twice daily) in two divided doses daily in 
combination with a placebo capsule. The second group 
(case group) was treated with sodium valproate tablet 
or syrup with a dose of 20 mg per kg of body weight 
(maximum 200 mg twice daily) in two divided doses 
daily in combination with an omega-3 capsule (Zahravi 
pharmaceutical company) containing 1 g of fish oil 
(180 mg eicosapentaenoic acid (EPA) and 120 mg 
docosahexaenoic acid (DHA)). Placebo capsules were 
prepared by Zahravi pharmaceutical company with a 
shape, color, and packaging quite similar to omega-3 
capsules and without any effective substances. After 
selecting the patients for inclusion into the project 
and offering explanations to the parents and to obtain 
informed consent, patients were randomly assigned 
to one of the two groups (A or B) and a code was 
assigned to them. Then, without informing the patients 
and the physician about the medication content of 
group A or B, medications were given to the patients 
by the physician and they were treated and followed 
for at least 2 months and the severity and frequency 
of headaches were recorded. The codes were unveiled 
after completion of the treatment duration and 
recording of patient information. In some patients, 
a brain CT scan and an MRI were conducted before 
starting the study. Moreover, these imaging measures 
were carried out based on the need in case of a change 
in the clinical symptoms during the study such that it 
was not justifiable with a diagnosis of migraine. If the 
diagnosis was changed, the person was excluded and 
replaced by another suitable for the study. Monthly 
assessments of patients were performed. Routine 
monitoring was performed for sodium valproate intake. 
Other appropriate medications were prescribed in cases 
could be the reasons for the increase (4). It is estimated 
that the average absence from school for children with 
migraines is 1.5 weeks higher than for peers (5). If the 
patients suffer from frequent headache attacks or with 
severe disabilities, they need to have daily preventive 
medication (3). Prophylactic treatment is an important 
part of migraine treatment and its goal is to reduce 
the frequency, severity, and duration of headaches as 
well as to improve the effect of medications to stop 
the headaches (6). These therapeutic measures include 
a variety of items such as pharmacological and non-
pharmacological methods, dietary supplements, and 
herbal ingredients (6). Conventional medications for 
children, which their preventive impact on migraine 
has been proven in clinical trial studies, include items 
such as sodium valproate, topiramate, propranolol, 
amitriptyline, naproxen, and flunarizine (7). Non-
pharmacological approaches focus on improving the 
quality of sleep, reducing daily stress, exercise, and 
modifying dietary patterns (6). The methods based 
on the dietary supplements and natural ingredients 
focus on the effects of L-carnitine, vitamin B-2, fish 
oil, omega-3, and magnesium in preventing migraines 
(8)(9)(10)(11). The use of omega-3 polyunsaturated 
fatty acids in the prevention or treatment of migraine 
has received much attention in recent studies (10)
(11)(12). Omega-3 interferes with the conversion 
of omega-6 to eicosanoids; therefore, reduces the 
production of prostaglandins and leukotrienes (11). 
The hypothesis of perivascular inflammation and 
neurogenic inflammation in incidences of migraines 
may explain the anti-inflammatory effects of omega-3 
to reduce migraines (11). The investigations carried out 
in this area were mostly in adults and with different 
results (10) (11) (12). The main purpose of this study 
was to compare the effects of omega-3 as an adjuvant 
in reducing the severity of migraine attacks in children.
 
Materials & Methods  
In this study, children aged 5–14 years of age who 
were referred to the Pediatric Neurology Clinic of 
Besat Hospital and Imam Khomeini Clinic of Hamedan 
with complaints of headache and were diagnosed with 
a migraine according to the International Headache 
Society Revised Criteria for Migraine in Children as 
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of the exacerbation of symptoms and no response to 
treatment. During the attacks, treatments were used 
to stop headaches if needed. The demographic data 
including age, gender, and information about the history 
and symptoms were recorded before starting treatment. 
The number of headache attacks per month before and 
after the treatment was recorded by questioning the 
parents. The severity of headaches before and after 
the treatment was evaluated according to the Pediatric 
Migraine Disability Assessment Score (PedMIDAS). 
The headache severity was divided into grade 1 (0–10), 
grade 2 (11–30), grade 3 (31–50), and grade 4 (greater 
than 50) according to the PedMIDAS questionnaire. 
Grade 1 had the lowest and grade 4 had the highest 
headache severity. Furthermore, Clinical General 
Impression (CGI) was evaluated using a 7-point Likert 
scale. Grade 1 is very dissatisfied and grade 7 is quite 
satisfied. Patients were revisited every two weeks for 2 
months after the treatment and the severity of migraine 
attacks after the treatment were evaluated. The outcome 
of the treatment in the two groups was analyzed using 
SPSS (ver 16) as the impact on the number of headache 
attacks and headache severity in each group.
This study was registered as an Iranian clinical trials 
with registration number IRCT2013092914809N1.
 
Results 
In the present study, 25 patients from the studied 
population were included in the project. The case group 
involved 12 patients who were treated with omega-3 
capsules and sodium valproate; and the control group 
included 13 patients who were treated with sodium 
valproate and a placebo. The mean age of patients in 
this study was 10.36 years (SD = 2.88). Gender analysis 
of the studied patients showed that of the 25 patients, 
11 patients were male (44%) and 14 were female 
(56%). The results of the demographic data showed no 
significant differences between the two groups.
The mean number of headache attacks per month before 
starting the treatment showed that the average in the 
case group was 13.75 attacks per month (SD = 8.36); 
and in the control group, this average was 16.30 attacks 
per month (SD = 10.38) (PV = 0.507). An assessment 
of the mean number of headache attacks per month 
after the treatment showed that in the case group the 
average was 2.91 attacks per month (SD = 2.91) and 
in the control group, the average was 3.15 attacks per 
month (SD = 3.15) (PV = 0.822). The number of attacks 
before and after the treatment decreased significantly 
in both groups (placebo: P = 0.000 and omega-3: P = 
0.000).
Evaluation of headache severity using PedMIDAS 
(grades 1–4) before the treatment showed that in the 
case group the average of this scale was 2.08 (SD = 
1.08); and in the control group, the average of this 
scale was 2 (SD = 0.92) (PV = 0.837). An evaluation 
of headache severity using PedMIDAS (grades 1–4) 
after the treatment showed that in the case group, the 
average of this scale was 1.08 (SD = 0.289) and in the 
control group, the average of this scale was 1 (SD = 
0.00) (PV = 0.308). The severity of symptoms before 
and after the treatment decreased significantly in both 
groups (placebo: P = 0.002 and omega-3: P = 0.004).
Assessment of the average of CGI (1–7) showed that in 
the case group the average was 6.08 (SD = 0.52); and 
in the control group, the average was 6.07 (SD = 0.65) 
(PV = 0.978).
As regards the side effects of omega-3, there was only 
one case of nausea after omega-3 intake where the 
patient was not willing to continue the treatment and 
the patient was excluded from the study. No other side 
effects were observed in the other patients.
 
Discussion 
Previous studies have been conducted recently on 
the effects of omega-3 in neurological diseases such 
as autism, dementia, depression, hyperactivity, and 
headaches (10) (13) (14) (15). 
Bloch et al. has demonstrated a small but significant 
benefit of omega-3 fatty acid supplementation in 
improving ADHD symptoms in a systematic review 
and meta-analysis study (16). Meta-regression also 
demonstrated a significant association between EPA 
dose within supplements (80–750 mg) and supplement 
efficacy.
In this study, we tried to determine which omega-3 is 
beneficial in treating child migraines. It was determined 
that omega-3 has no effect on reducing the frequency 
and severity of migraine attacks in children. However, 
the outcome of treatment with sodium valproate 
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Table 1. Comparison of Demographic and Clinical Characteristics of Migraine and Control Group. 
Control GroupCase Group
PV=0.8212.74± 23/103.147±5/10Mean age (yr)
PV=0.8016/75/7Male/ female
PV=0.125016.7%History of Seizure
PV=0.8705/85/7Classic Migraine/ Common Migraine
PV=0.49092.3 %83.3 %Familial History of Migraine 
differences between the two treatments in terms of 
reducing the frequency of headaches (12). Different 
patients age and evaluation methods are probably the 
main reasons for the different result in our study.  
In conclusion, although omega-3 was less effective 
than a placebo in our study, it seems that conducting 
other studies with larger sample sizes and if possible 
without the presence of other preventive medications 
may lead to different results.
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showed that it was significantly effective in both 
groups. Tajmirriahi et al. investigated the effects of fish 
oil (1 g omega-3 capsule) in combination with sodium 
valproate compared to placebo and sodium valproate 
in 68 adult patients. Patient headache severity (by 
a 10-point visual analog scale, VAS), frequency of 
headache per month, and duration of headache were 
determined before and after 1, 2, and 3 months of 
treatment. There was a significant reduction in headache 
frequency (P = 0.044) and headache severity (P = 0.046) 
in the case group after the first month (10). Harel et 
al. compared the prophylactic effects of omega-3 with 
a placebo (olive oil) on 23 patients with a history of 
migraines that led to positive results and omega-3 oil 
significantly reduced the frequency of migraine attacks 
(11). Pradelier et al. indicated from the daily intake of 
6 g of omega-3 versus placebo for 4 months did not 
show positive results in the management of migraines. 
In this study, 198 patients with a history of recurrent 
migraine were first treated with omega-3 oil and then 
discontinued the drugs and again, one month later they 
were treated with a placebo. There were no significant 
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